Dr Reddy's closes Wockhardt branded generics deal on modified terms

Under new terms, DRL to hold back Rs 300 crore and release it if the revenue from sale of the products forming part of the business undertaking during the 12 months post-closing exceeds Rs 480 cr

Dr Reddy's

Under the new terms, an amount of Rs 1,483 crore would be paid on the date of closing.

Dr Reddy's Laboratories Limited today announced that it has completed the acquisition of select divisions of Wockhardt Limited's branded generics business in India and a few other international territories of

Also Read

New launches, regulatory go-ahead key triggers for Dr Reddy's

Wockhardt sells part of branded biz to Dr Reddy's for Rs 1850 crore

Dr Reddy's hits 52-week high after USFDA issues EIR for Srikakulam facility

Dr Reddy's posts Rs 570-cr net loss due to heavy impairment charge

Dr Reddy's reaping benefits of domestic market focus, outperforms peers

SAIL partners Apollo for healthcare services to employees, their families

Two firefighters dead in gas well blowout blaze in Assam, says Oil India

IndianOil refineries' throughput crosses 80% on the back of higher demand

Independent kin aren't public shareholders, Sebi tells Mirza International

Anand Mahindra invests $1 million in social network start-up Hapramp

First Published: Jun 10 2020 | 5:22 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to